PM Tracker

Johnson & Johnson and partner Legend Biotech already sell BCMA-targeted CAR-T therapy Carvykti. Now, the company has complemented that complex therapy with an off-the-shelf option.

Just a few months after Fitbit roped in FDA clearance for an algorithm that could be embedded into its eponymous health-tracking wearables to detect atrial fibrillation, the technology is ready to hit the ground running.

More than a month after axing 94 employees, PACT Pharma is culling its lead asset and diverting 54 of the laid-off employees to a new business development venture that's yet to be named.

The European Commission gave Roctavian the all-clear, granting conditional marketing authorization to the med in adults with severe hemophilia A who don’t have factor VIII inhibitors.

Employers view long-term mental health as the key healthcare issue coming out of COVID-19, according to a new survey.

With a device that’s now been cleared in both the U.S. and Europe, preparing a patient for an EEG test is almost as easy as strapping on a bike helmet.

Pfizer has kept up the heat on GSK in the respiratory syncytial virus (RSV) vaccine race, joining its rival in posting positive phase 3 data and staying tucked in its slipstream with plans to seek approval in the fall.

A $1.7 billion loss from investments would have dragged Intermountain well into the red were it not for more than $4.1 billion in affiliation contributions resulting from the merger deal.

Less than a year into a strategic review, Novartis has decided to spin off its generics unit Sandoz. The separation will allow both companies to pursue different capital allocation strategies, CEO Vas Narasimhan, M.D., said.

Aktis Oncology has closed a series A extension round to the tune of $84 million, with big pharmas Merck Novartis and BMS joining to expand the biotech’s bandwidth for developing radiopharmaceutical cancer treatments.

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.

Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella.

Set a solid foundation for successful scale-up of buffer preparation.

The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services.

See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead.

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry.

Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays?

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.